What is Wedbush’s Estimate for Zenas Biopharma Q2 Earnings?

Zenas Biopharma Inc (NASDAQ:ZBIO) – Investment analysts at Wedbush raised their Q2 2025 earnings per share estimates for shares of Zenas Biopharma in a research note issued on Thursday, May 15th. Wedbush analyst M. Fan now anticipates that the company will post earnings of ($1.03) per share for the quarter, up from their prior estimate of ($1.11). Wedbush currently has a “Outperform” rating and a $35.00 target price on the stock. Wedbush also issued estimates for Zenas Biopharma’s Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.79) EPS, Q1 2026 earnings at ($1.04) EPS, Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.97) EPS, FY2026 earnings at ($4.00) EPS, FY2028 earnings at ($2.35) EPS and FY2029 earnings at ($0.49) EPS.

Several other analysts have also recently issued reports on ZBIO. Guggenheim reaffirmed a “buy” rating and issued a $45.00 price target on shares of Zenas Biopharma in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Zenas Biopharma in a research note on Friday.

Zenas Biopharma Stock Up 5.2%

Shares of Zenas Biopharma stock opened at $11.01 on Monday. Zenas Biopharma has a 1-year low of $5.83 and a 1-year high of $26.25. The firm has a market capitalization of $460.59 million and a P/E ratio of -3.10. The firm’s 50-day simple moving average is $8.96.

Zenas Biopharma (NASDAQ:ZBIO) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.35. The company had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $5.00 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. New York State Common Retirement Fund acquired a new stake in Zenas Biopharma in the first quarter worth approximately $49,000. Jefferies Financial Group Inc. acquired a new position in shares of Zenas Biopharma during the 1st quarter valued at $348,000. Finally, Nuveen LLC bought a new stake in shares of Zenas Biopharma in the 1st quarter worth $250,000.

About Zenas Biopharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.